ENEric Nisenbaum

Eric Nisenbaum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Nisenbaum has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • A Eliot Shearer

    Department of Otolaryngology-Head and Neck Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

    1 shared publication
  • Denise Yan

    Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA

    1 shared publication
  • Elizabeth Nicolli

    Department of Otolaryngology, University of Miami Miller School of Medicine

    1 shared publication
  • Evan de Joya

    Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA

    1 shared publication
  • Hinrich Staecker

    Department of Otolaryngology Head and Neck Surgery, University of Kansas Health System, Kansas City, Kansas, USA

    1 shared publication
  • Jeffrey R. Holt

    Departments of Otolaryngology & Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA

    1 shared publication

Latest Publications

  • Genotype-Phenotype Correlations in TMPRSS3 (DFNB10/DFNB8) with Emphasis on Natural History

    by Eric Nisenbaum, Denise Yan, A Eliot Shearer, Evan de Joya, Torin Thielhelm, Nicole Russell, Hinrich Staecker, Zhengyi Chen, Jeffrey R. Holt, Xuezhong Liu

    Background: Mutations in TMPRSS3 are an important cause of autosomal recessive non-syndromic hearing loss. The hearing loss associated with mutations in TMPRSS3 is characterized by phenotypic heterogeneity, ranging from mild to profound hearing loss, and is generally progressive. Clinical presentation and natural history of TMPRSS3 mutations vary significantly based on the location and type of mutation in the gene. Understanding these genotype-phenotype relationships and associated natural disease histories is necessary for the successful development and application of gene-based therapies and precision medicine approaches to DFNB8/10. The heterogeneous presentation of TMPRSS3-associated disease makes it difficult to identify patients clinically. As the body of literature on TMPRSS3-associated deafness grows, there is need for better categorization of the hearing phenotypes associated with specific mutations in the gene. Summary: In this review, we summarize TMPRSS3 genotype-phenotype relationships including a thorough description of the natural history of patients with TMPRSS3-associated hearing loss to lay the groundwork for the future of TMPRSS3 treatment using molecular therapy. Key Messages: TMPRSS3 mutation is a significant cause of genetic hearing loss. All patients with TMPRSS3 mutation display severe-to-profound prelingual (DFNB10) or a postlingual (DFNB8) progressive sensorineural hearing loss. Importantly, TMPRSS3 mutations have not been associated with middle ear or vestibular deficits. The c.916G>A (p.Ala306Thr) missense mutation is the most frequently reported mutation across populations and should be further explored as a target for molecular therapy.